Delayed onset of action of antidepressants: Fact or fiction?

CNS Drugs

Volumn 9, Issue 3, 1998, Pages 177-184

  Stassen, Hans H ^a   Angst, Jules ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; HAMILTON SCALE; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031958287     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809030-00001     Document Type: Review

References (34)

1. Weissman MM, Bruce ML, Leaf PJ. Affective disorders. In: Robins L, Regier D, editors. Affective disorders. New York: Free Press, 1991: 53-80
2. Angst J. The epidemiology of depressive disorders. Eur Neuropsychopharmacol 1995; 5 Suppl.: 95-8
3. Wilhelm K, Parker G. Sex differences in lifetime depression rates: fact or artefact? Psychol Med 1994; 24: 97-111
4. Lavori PW, Warshaw M, Klerman G, et al. Secular trends in lifetime onset of MDD stratified by selected socio-demographic risk factors. J Psychiatr Res 1993; 27: 95-109
5. Giuffra LA, Risch N. Diminished recall and the cohort effect of major depression: a simulation study. Psychol Med 1994; 24: 375-83
6. Simon GE, von Korff M, Ustun TB, et al. Is the lifetime risk of depression actually increasing? J Clin Epidemiol 1995; 48: 1109-18
7. Murphy JM. Incidence of mental disorder [letter]. Br J Psychiatry 1996; 169: 667-8
8. Stassen HH, Ragaz M, Reich T. Age-of-onset or age-cohort changes in the lifetime occurence of depression? Psychiatr Genet 1997; 7: 27-34
9. Kendler KS, Pedersen N, Johnson L, et al. A pilot Swedish twin study of affective illness, including hospital- and population-ascertained subsamples. Arch Gen Psychiatry 1993; 50: 699-706
10. Wender PH, Kety SS, Rosenthal D, et al. Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry 1986; 43: 923-9
11. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response. Arch Gen Psychiatry 1987; 44: 259-64
12. Quitkin FM, McGrath PJ, Stewart JW, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology 1996; 15: 390-4
13. Parker G. On brightening up: triggers and trajectories to recovery from depression. Br J Psychiatry 1996; 168: 263-4
14. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987; 17: 297-309
15. Khan A, Cohen S, Dager S, et al. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord 1989; 17: 33-8
16. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Psychopharmacol 1993; 3: 127-35
17. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994; 9: 245-50
18. Montgomery SA. Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 1995; 10 Suppl. 2: 21-7
19. Möller HJ, Müller H, Volz HP. How to assess the onset of antidepressant effect: comparison of global ratings and findings based on depression scales. Pharmacopsychiatry 1996; 29: 57-62
20. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich metaanalyses. Pharmacopsychiatry 1996; 29: 87-96
21. Greenhouse JB, Stangl D, Bromberg J. An introduction to survival analysis: statistical methods for analysis of clinical trial data. J Cons Clin Psychology 1989; 57: 536-44
22. Laska EM, Meisner MJ. Nonparametric estimation and testing in a cure model. Biometrics 1992; 48: 1223-34
23. Hamilton M. Hamilton depression scale. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville (MD): Chevy Chase, 1976: 179-92
24. Angst J, Delini-Stula A, Stabl M, et al. Is a cut-off score a suitable measure of treatment outcome in short-term trials in depression? A methodological meta-analysis. Hum Psychopharmacol 1993; 8: 311-7
25. Quitkin FM, Stewart JW, McGrath PJ, et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993; 150: 566-70
26. Fairchild CJ, Rush AJ, Vasavada N, et al. Which depression responds to placebo? Psychiatry Res 1986; 18: 217-26
27. Rush AJ, Weissenburger JE. Melancholic symptom features and DSM-IV. Am J Psychiatry 1994; 151: 489-98
28. Kuny S, Stassen HH. Speaking behavior and voice sound characteristics in depressive patients during recovery. J Psychiatr Res 1993; 27: 289-307
29. Stassen HH. Affekt und Sprache. Stimm- und Sprachanalysen bei Gesunden, depressiven und schizophrenen Patienten. Monographien aus dem Gesamtgebiete der Psychiatrie, Bd. 79. Berlin-Heidelberg: Springer Verlag, 1995
30. Stassen HH, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacol. In press
31. Angst J, Stassen HH. Methodische Aspekte von Studien zur antidepressiven Wirksamkeit. In: Steinberg R, Philipp M, Möller HJ, editors. Spezielle Aspekte der antidepressiven Therapie. München: MMV Medizin Verlag, 1994: 147-66
32. Kuhn R. Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat. Schweiz Med Wochenschr 1957; 87: 1135-40
33. Angst J. Mechanism of action of imipramine and its therapeutic use. In: Angst J, editor. Tofranil. Bern: Stämpfli & Cie, 1970: 36-54
34. Parker G. Recovery from depression: triggers and time patterns. Aust NZ J Psychiatry 1996; 30: 442-4